Takeda/Amylin's Pramlintide/Metreleptin Combo Becomes The Latest Obesity Casualty
This article was originally published in PharmAsia News
Executive Summary
Development of a once-promising combination of pramlintide and metreleptin for obesity has been discontinued after a "commercial reassessment," U.S.-based Amylin Pharmaceuticals Inc. and Japan's Takeda Pharmaceutical Company Limited announced Aug. 4